NRx Pharma posts FY2024 operating loss of $18.5M; NDA filings for ketamine and bipolar drug anticipated in 2025

NRX Pharmaceuticals, Inc.

Q4 2024 operating loss $2.4M, down 45% YoY; FY2024 operating loss $18.5M vs $27.8M in 2023.
Received non-binding terms for NRX-100 license with >$300M milestones plus double-digit royalties.
Initiated NDA for NRX-100 (IV ketamine) and plans NDA for NRX-101 (bipolar depression); both target PDUFA dates before Dec 31, 2025.
HOPE Therapeutics signed LOIs to acquire three precision psychiatry centers; negotiating for six more; BTIG engaged as advisor.
Cash $1.4M at Dec 31, 2024; raised $8.5M in Jan 2025; management expects sufficient cash through end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.